The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Thoas Fioretos

Thoas Fioretos

Research team manager

Thoas Fioretos

Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer.

Author

  • Linda Holmquist Mengelbier
  • Jenny Karlsson
  • David Lindgren
  • Anders Valind
  • Henrik Lilljebjörn
  • Caroline Jansson
  • Daniel Bexell
  • Noémie Braekeveldt
  • Adam Ameur
  • Tord Jonson
  • Hanna Göransson Kultima
  • Anders Isaksson
  • Jurate Asmundsson
  • Rogier Versteeg
  • Marianne Rissler
  • Thoas Fioretos
  • Bengt Sandstedt
  • Anna Börjesson
  • Torbjörn Backman
  • Niklas Pal
  • Ingrid Øra
  • Markus Mayrhofer
  • David Gisselsson Nord
Show all

Summary, in English

Genetic differences among neoplastic cells within the same tumour have been proposed to drive cancer progression and treatment failure. Whether data on intratumoral diversity can be used to predict clinical outcome remains unclear. We here address this issue by quantifying genetic intratumoral diversity in a set of chemotherapy-treated childhood tumours. By analysis of multiple tumour samples from seven patients we demonstrate intratumoral diversity in all patients analysed after chemotherapy, typically presenting as multiple clones within a single millimetre-sized tumour sample (microdiversity). We show that microdiversity often acts as the foundation for further genome evolution in metastases. In addition, we find that microdiversity predicts poor cancer-specific survival (60%; P=0.009), independent of other risk factors, in a cohort of 44 patients with chemotherapy-treated childhood kidney cancer. Survival was 100% for patients lacking microdiversity. Thus, intratumoral genetic diversity is common in childhood cancers after chemotherapy and may be an important factor behind treatment failure.

Department/s

  • Pathways of cancer cell evolution
  • Molecular Pediatric Oncology
  • Division of Clinical Genetics
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Division of Translational Cancer Research
  • Division of Clinical Chemistry and Pharmacology
  • Paediatrics (Lund)

Publishing year

2015

Language

English

Publication/Series

Nature Communications

Volume

6

Document type

Journal article

Publisher

Nature Publishing Group

Topic

  • Cancer and Oncology
  • Medical Genetics
  • Pediatrics

Status

Published

Research group

  • Pathways of cancer cell evolution
  • Molecular Pediatric Oncology

ISBN/ISSN/Other

  • ISSN: 2041-1723